Mar 20, 2025 · 32m · a16z
Scaling Medicaid Innovation with Rajaie Batniji, Sanjay Basu, and Afia Asamoah
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In this panel discussion hosted by a16z's Vineeta Agarwala, Waymark co-founders Rajaie Batniji, Afia Asamoah, and Sanjay Basu detail how their public benefit corporation combines community-based care teams, predictive machine learning, and innovative value-based contracting to improve health outcomes and reduce costs for Medicaid populations.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. How this is scored →
speaking balance: gold is the host, purple is the guest (3 minute bins)
Rajaie humorously reframes Vineeta's biopharma analogy with a provocative claim that withholding their non-drug intervention would constitute medical malpractice.
Hardest push from the host ▶ 20:15 Challenging market execution barriersVineeta directly challenges the guests on market reality by asking why other healthcare organizations fail to target rising-risk populations if the strategy is standard.
Biggest teaching moment ▶ 18:07 Flaws in traditional high-cost claimant algorithmsRajaie educates the host on how standard Medicaid predictive algorithms identify high-cost patients only after their spend trajectory has already peaked and started declining naturally.
The host holds their own ▶ 25:23 Biopharma precision medicine parallelVineeta demonstrates high expertise by reframing the conversation using advanced pharma concepts like precision biomarkers and number needed to treat to evaluate AI model rigor.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | The host as informed peer | Guest teaching | Guest disagreement | The host pushing back | Why |
|---|---|---|---|---|---|---|
| Afia Asamoah's Background and Journey to Waymark | 3 | 2 | 0 | 0 | Vineeta opens the interview by asking Afia about her background transitioning from law into health tech product development at Google. Afia provides a collaborative narrative about her career and motivation for joining Waymark. | |
| Sanjay Basu on Clinical Practice and Social Interventions | 4 | 3 | 0 | 0 | Vineeta frames Sanjay's dual role as clinical lead and practicing primary care physician before turning to Rajaie's background as a repeat founder. The exchange is warm and informative, establishing company origin stories. | |
| The Care Delivery Model: Moving Care into Communities | 4 | 5 | 1 | 1 | Vineeta notes that roughly 20-25 percent of Americans rely on Medicaid and gently questions how a tiny startup of three people could address such a daunting challenge. Rajaie explains that 39 percent of Medicaid acute care is avoidable and details how productizing community health worker interventions makes scaling possible. | |
| Waymark's Structure as a Public Benefit Corporation | 3 | 3 | 0 | 0 | Vineeta validates Waymark's product strategy before asking Afia to explain the choice to incorporate as a Public Benefit Corporation. Afia describes how a PBC structure binds leadership to a dual fiduciary and social charter. | |
| NEJM Catalyst Study Results and Machine Learning Signal | 5 | 6 | 1 | 1 | Vineeta introduces the New England Journal Catalyst study results and asks probing follow-up questions regarding clinical mechanics. Sanjay and Rajaie present trial results showing a 23 percent reduction in ER visits driven by machine learning risk prediction. | |
| Defining and Targeting the Rising Risk Patient Population | 6 | 5 | 1 | 3 | Vineeta pushes the guests on market friction, asking why other health groups fail to target rising-risk patients if the strategy is so obvious. Rajaie and Afia explain why legacy algorithms miss rising-risk cohorts and how risk-based contracting enables community care. | |
| Participatory Data Science and AI Task Automation | 8 | 4 | 2 | 2 | Vineeta demonstrates impressive domain mastery by connecting Waymark's machine learning model to biopharma clinical trial concepts like precision biomarkers and numbers needed to treat. Rajaie responds with a witty comment that if their model were a drug, withholding it would be medical malpractice. | |
| Scaling Strategy, Value-Based Care, and Community Networks | 7 | 5 | 2 | 2 | Vineeta actively builds on Rajaie's criticism of 'value veneers' in Medicaid, elaborating on how superficial ACO contracts lack actual care delivery resources. The guests discuss local community trust and wrap up the discussion. |